Back to today’s briefing

Story perspectives

Novavax Seeks FDA Approval Amid Vaccine Landscape Shift

4/30/2025

42 8

Summary

Novavax Seeks Approval

Novavax is pushing for full FDA approval of its COVID-19 vaccine after facing delays for more clinical data. With new FDA leadership prioritizing strict scientific standards, fears of political influence loom. This traditional protein-based vaccine could offer wider protection and attract those wary of mRNA options, potentially reshaping the vaccination landscape.

Summary

Merck Boosts Production

Merck is set to invest a staggering $1 billion in a new manufacturing plant in Delaware, boosting the production of its flagship cancer drug, Keytruda. This strategic move aims to secure a reliable domestic supply amidst increasing tariffs. However, the FDA's workforce cuts are causing significant delays in drug approvals, leaving companies like Stealth BioTherapeutics and Vanda Pharmaceuticals grappling with regulatory hurdles.

1 of 2

Novavax Seeks Approval

Novavax is pushing for full FDA approval of its COVID-19 vaccine after facing delays for more clinical data. With new FDA leadership prioritizing strict scientific standards, fears of political influence loom. This traditional protein-based vaccine could offer wider protection and attract those wary of mRNA options, potentially reshaping the vaccination landscape.

1 / 2